[144] Mineralys Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) has filed a Form 144 indicating a planned sale of 15,884 common shares through broker Merrill Lynch. Based on the stated aggregate market value, the transaction is valued at approximately $230,430. The shares were acquired on 07/10/2025 via the vesting of a restricted stock unit award granted under the company’s equity-compensation plan and are expected to be sold on or after 07/11/2025 on the NASDAQ.

The filing shows 65,175,287 shares outstanding; the proposed sale therefore represents roughly 0.02 % of total shares. No other sales by the filer have occurred in the past three months, and no material adverse information was asserted in the certification section.

Insights

Securities Analyst

TL;DR: Small insider sale (~0.02 % of float) via RSU vesting; minimal market impact expected.

The Form 144 discloses a routine disposition of 15,884 shares valued at about $230k, stemming from equity compensation. Relative to the 65.2 million shares outstanding, the transaction is immaterial and unlikely to influence supply-demand dynamics or investor sentiment in a meaningful way. The absence of prior sales in the last three months further limits signaling value. Overall, the filing is informational rather than impactful.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15884	230430.05	65175287	07/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/10/2025	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			15884	07/10/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Mineralys Therapeutics (MLYS) shares are being sold under the Form 144?

The notice covers 15,884 common shares.

What is the approximate market value of the proposed share sale?

The aggregate market value is stated as $230,430.05.

When is the expected sale date for the MLYS shares?

The filing lists an approximate sale date of 07/11/2025.

How were the shares to be sold acquired?

They were obtained on 07/10/2025 through the vesting of a restricted stock unit award granted under the company’s equity plan.

What percentage of Mineralys Therapeutics’ outstanding shares does the sale represent?

With 65,175,287 shares outstanding, the 15,884-share sale equals roughly 0.02 % of total shares.

Which broker is handling the transaction?

The shares will be sold through Merrill Lynch, 225 Liberty St, New York, NY 10281.

Were any other shares sold by the filer in the past three months?

No. The filing states "Nothing to Report" for prior 3-month sales.